Vienna, (Austria), September 9, 2011 -- Hermann A.M. Mucke, H.M. Pharma Consultancy's owner and manager, released the following statement today:

"The first eight months of 2011 have seen us working hard, and though much of this is under customer confidentiality we continue to build a presence as a life science information provider. Our media strategy, outlined last December, has been most successful. The LinkedIn discussion group "Drug Repurposing - Repositioning" has become one of the most vivid special-focus pharma groups on this professional platform, and is approaching 250 members. Our blog at hmpharmacon.blogspot.com where we publish short commentaries and monthly patent analyses continues to attract more visitors; our Twitter presence is honored to see a dynamic quality followership from industry and academia.

A few weeks ago our report on protein and antibody engineering was published in a new interactive format, again with our long-term market and technology analysis partner Insight Pharma Reports. Another report will be published later this year. We have already made several other publishing arrangements for 2012 and are confident that our customers will continue to call on us in these difficult times for the pharmaceutical industry."